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Abstract
Mutations in PIK3CA are present in 10 to 15% of colorectal carcinomas. We aimed to examine how PIK3CA mutations relate
to other molecular alterations in colorectal carcinoma, to pathologic phenotype and survival. PIK3CA mutation testing was
carried out using direct sequencing on 757 incident tumors from the Melbourne Collaborative Cohort Study. The status of
O-6-methylguanine-DNA methyltransferase (MGMT) was assessed using both immunohistochemistry and methyLight
techniques. Microsatellite instability, CpG island phenotype (CIMP), KRAS and BRAF V600E mutation status, and pathology
review features were derived from previous reports. PIK3CA mutation was observed in 105 of 757 (14%) of carcinomas,
characterized by location in the proximal colon (54% vs. 34%; P,0.001) and an increased frequency of KRAS mutation (48%
vs. 25%; P,0.001). High-levels of CIMP were more frequently found in PIK3CA-mutated tumors compared with PIK3CA wild-
type tumors (22% vs. 11%; P= 0.004). There was no difference in the prevalence of BRAF V600E mutation between these two
tumor groups. PIK3CA-mutated tumors were associated with loss of MGMT expression (35% vs. 20%; P= 0.001) and the
presence of tumor mucinous differentiation (54% vs. 32%; P,0.001). In patients with wild-type BRAF tumors, PIK3CA
mutation was associated with poor survival (HR 1.51 95% CI 1.04–2.19, P= 0.03). In summary, PIK3CA-mutated colorectal
carcinomas are more likely to develop in the proximal colon, to demonstrate high levels of CIMP, KRAS mutation and loss of
MGMT expression. PIK3CA mutation also contributes to significantly decreased survival for patients with wild-type BRAF
tumors.
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Introduction
PIK3CA (phosphatidylinositol-3,4-bisphosphonate 3-kinase, catalytic
subunit alpha) encodes for the catalytic p110-alpha subunit of
Phosphatidylinositol 3-Kinase (PI3K) alpha, which orchestrates
cell responses including cell proliferation, survival, proliferation,
migration and morphology [1,2]. PI3K is a family of proteins
capable of phosphorylating phosphaditylinositols in response to
activation of growth factors from various ligands such as epidermal
growth factor (EGF), insulin, platelet-derived growth factor
(PDGF) or vascular endothelial growth factor (VEGF). The
PI3K pathway is normally inhibited by tumor suppressor gene
PTEN [3]. Alterations in PI3K signaling pathway are frequent
events in various tumor types either through inactivation of PTEN
or by amplification or mutation in PIK3CA. Activating mutations
in PIK3CA have been found in neoplasms of the colorectum,
stomach, breast, brain, ovaries, liver and lung [4,5]. These
mutations are concentrated in 2 hot spots of the gene: the helical
domain in codons 542 and 545 of exon 9 and the kinase domain in
codon 1047 of exon 20. A gain of transformative enzymatic
function in both cell lines and orthotopic models results from
mutation within both regions [6,7]. For colorectal carcinoma, the
prevalence of PIK3CA mutation was reported to be between 7%
and 32%, with G.A transversions in exon 9 being the most
commonly observed configuration
[4,8,9,10,11,12,13,14,15,16,17,18,19,20,21].
Recent interest arose for PIK3CA as a potential predictive
marker of personalized therapy for colorectal carcinoma and a
target for specific pharmaceutical agents. PIK3CA is a downstream
effector of Epidermal Growth Factor Receptor (EGFR), a target
for monoclonal antibodies such as cetuximab and panitumumab,
leading to inhibition of its signaling cascade. The clinical benefit of
this targeted therapy is restricted to wild-type KRAS colorectal
carcinoma [22,23]. It has been suggested that the deregulation of
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PIK3CA/PTEN might also influence the response to EGFR
inhibitors in metastatic disease [24,25]. PI3K represents a
potential new target for specific therapeutic inhibitors with
promising molecules currently under clinical trials [26]. More
recently, PIK3CA mutation was associated with longer survival in
patients who use aspirin regularly after diagnosis [27].
The study of the molecular pathology of PIK3CA-mutated
colorectal carcinoma has produced some conflicting results, as
displayed in table 1, in particular, its association with CpG Island
Methylator Phenotype (CIMP) and O-6-methylguanine-DNA
methyltransferase (MGMT) status [12,13,17,18,21,25,28,29,30].
The relationship between PIK3CA mutation and other molecular
pathologic features such as microsatellite instability (MSI) has not
been explored in detail. It is unclear whether PIK3CA mutation
defines a clinically and/or biologically relevant subset of tumors as
there is significant overlap with KRAS and BRAF V600E mutation.
Clinical studies testing the effect of PIK3CA mutation on patient
outcomes have produced conflicting results
[8,9,13,15,17,19,28,31,32], with the majority of studies showing
a mild adverse prognostic effect of PIK3CA mutation in various
subgroups of patient. Our aim was to explore the clinical,
molecular and pathologic characteristics of incident PIK3CA-
mutated colorectal carcinomas from a large prospective cohort
study.
Patients and Methods
Study Samples
Participants were enrolled in The Melbourne Collaborative
Cohort Study, a prospective cohort study of 41,514 people (17,045
males and 24,469 females) recruited between 1990 and 1994. The
design and recruitment of this study have been previously
described in detail [33]. The study protocol was approved by
the Cancer Council Victoria’s Human Research Ethics Commit-
tee and the Human Research Ethics Committee of the Queens-
land Institute of Medical Research under protocol P799.
Participants gave written consent for participation and for the
investigators to obtain their medical records. Clinical data were
collected from medical charts, colonoscopy and pathology reports.
Location in the colon was designated as proximal for tumors
located in the cecum, ascending colon and transverse colon and as
distal in the descending colon, sigmoid colon and rectum.
Molecular Pathology
All cases underwent standardized histopathology review by a
specialist gastrointestinal pathologist and assessed histologically for
the following features: histologic type, mucinous differentiation,
grade, tumor margin (circumscribed or infiltrative), tumor budding
(non-quantitative method), the presence of tumor infiltrating
lymphocytes, and the presence of a residual polyp adjacent to the
carcinoma. Mucinous differentiation in the tumor was defined by
the presence of pools of extracellular mucin containing clusters of
carcinomatous cells or individual tumor cells, including signet ring
cells. Tumors were classified as mucinous carcinoma when .50%
of analyzed tumor demonstrated mucinous differentiation. Histo-
logic grading was performed as follows: conventional carcinomas
were classified as low grade if $50% gland formation was present
and high grade if ,50% gland formation was present; mucinous
carcinomas were graded according to the MSI phenotype: low
grade if MSI-high was present, high grade if MSI-high was absent.
Immunohistochemistry for mismatch repair proteins MLH1,
PMS2, MSH2, MSH6, and for MGMT have been described in
previous reports [34,35]. Tumors showing complete loss of
expression compared with the normal colonic mucosa were
interpreted as having altered expression of MGMT.
High levels of CpG Island methylator phenotype (CIMP) were
defined by methylation of $3 of the following markers RUNX3,
SOCS1, NEUROG1, CACNA1G, and IGF2. MLH1 gene promoter
methylation, BRAF V600E mutation analysis, mutations in codons
12 and 13 of KRAS, MSI phenotype, and MGMT methylation
were assessed using techniques described previously [33,36,37].
Putative Lynch syndrome tumors were defined as tumors with one
of the following characteristics: loss of immunohistochemical
expression of MSH2 and MSH6, MSH6 alone, PMS2 alone, or
MLH1 and PMS2 with wild-type BRAF and/or absence of MLH1
methylation.
Mutations within exon 9 and exon 20 of the PIK3CA gene were
assessed for each CRC case as follows. Briefly, 50–100 ng of
formalin-fixed paraffin-embedded (FFPE) tumor DNA was ampli-
fied in a 15 ml PCR containing 7.5 ml of GoTaq master mix
(Promega, Madison, WI, USA) and 5 pmoles of each primer (exon
9 forward 59-GGG AAA AA TATG ACA AAG AAA GCT A-39
and reverse 59-TCC ATT TTA GCA CTT ACC TGT GAC-39;
exon 20 forward 59-TTC TCA ATG ATG CTT GGC TCT
GGA A-39 and reverse 59-AAT GCA TGC TGT TTA ATT
GTG TGG A-39). Reactions were cycled on a Biorad iCycler
(Biorad, Hercules, CA, USA) using the following profile: 94uC for
2 minutes, followed by 45 cycles of 94uC for 15 seconds, 60uC for
15 seconds and 72uC for 15 seconds, cycling is finalized at 72uC
for 5 minutes. PCR reactions were subsequently cleaned up using
Montage PCR96 Cleanup plates (Millipore, Bedford, MA, USA)
according to the manufacturer’s guidelines. Depending on the
quality of the PCR product 1–4 ml was then used in an 8 ml
sequencing reaction comprising 0.4 ml BigDye Terminator v3.1,
1.4 ml 5x reaction buffer and 1.5pmoles of primer (exon 9 59-TAG
CTA GAG ACA ATG AAT TAA GGG AAA-39; exon 20 59-
TCT CAA TGA TGC TTG GCT CTG GAA-39). Reactions
were cycled for 96uC for 1 minute, followed by 25 cycles of 96uC
for 10 seconds, 50uC for 5 seconds and 60uC for 90 seconds. Prior
to running on an ABI3100 genetic analyzer (Applied Biosystems,
Foster City, CA, USA), sequencing reactions were cleaned up
using Xterminator reagent (Applied Biosystems, Foster City, CA,
USA) according to the manufacturer’s instructions. Resultant
sequences were analyzed using SeqMan software (DNASTAR,
Madison, WI, USA).
Statistical Analysis
Statistical analyses were performed with SPSS statistics software
version 19.0 (SPSS Inc., Chicago, IL) for group comparisons and
Stata version 11.1 (College Station, TX: StataCorp LP) for
survival analysis. Comparisons for categorical variables were
performed using Pearson’s chi-squared test or Fisher’s exact test
where appropriate. Student’s t-test was used for comparisons of
continuous variables.
Kaplan-Meier methods were used to estimate the survival by
PIK3CA status (wild-type vs. mutated), with death from all causes
as the endpoint and time measured from date of surgery until
death or 31 December 2008, whichever came first. Survival was
compared using the log-rank test. Cox regression models were
used to estimate hazard ratios (HRs) associated with PIK3CA (wild-
type vs. mutated), adjusting for: sex, age at diagnosis (,60, 60–70,
.70 years), tumor location (proximal vs. distal), histologic grade
(high vs. low), MSI status (MSI-high vs. non MSI-high), MGMT
expression (normal vs. loss), KRAS and BRAF status (wild-type vs.
mutated). This Cox regression was fitted for the whole cohort of
patients and also after exclusion of patients with a BRAF mutated
tumor. Results are presented as estimated HRs with 95%
PIK3CA Mutation in Colorectal Carcinoma
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confidence intervals (CI) and Wald-test P values. The proportional
hazards assumption was assessed using graphical methods and
tests based on Schoenfeld residuals. A two-tailed P value was used
for all analyses and values less than 0.05 were considered to be
statistically significant.
Results
Clinical and Pathologic Characteristics of PIK3CA-mutated
Colorectal Carcinoma
A complete set of clinical and molecular data was available for
757 patients. Characteristics of PIK3CA-mutated tumors are
shown in Table 2. PIK3CA mutation was detected in 105 tumors
(14%). The frequency of PIK3CA mutation did not differ
significantly between males and females (P=0.56), or between
persons of Anglo-Celtic or southern European ethnicity (P=0.22).
No significant difference was found in age at diagnosis between
patients with a PIK3CA-mutated carcinoma and those with wild-
type PIK3CA carcinoma (P=0.12). Compared with PIK3CA wild-
type tumors, PIK3CA-mutated tumors were predominantly
distributed in the proximal colon (54% vs. 34%, P,0.001) and
were associated with focal or prominent mucinous differentiation
(54% vs. 32%, P,0.001). Figure 1 displays the frequencies of
PIK3CA mutation in each segment of the large bowel, demon-
strating a gradual decrease from the cecum to the rectum. No
significant association was found with regard to tumor margin,
histologic grade, lymph node status, or the presence of synchro-
nous carcinoma or contiguous polyp (Table 2).
Associations of PIK3CA Mutation with Other Molecular
Markers
We investigated associations between PIK3CA mutation and
other molecular markers of colorectal carcinoma (Table 3;
Figure 2). KRAS mutation was present in 50 of 105 (48%)
PIK3CA-mutated tumors compared with 165 of 652 (25%) PIK3CA
wild-type tumors (P,0.001). In addition, PIK3CA-mutated tumors
were more likely to demonstrate high levels of CIMP (22%) when
compared with PIK3CA wild-type tumors (11%) (P=0.004).
Though BRAF mutation was present in 14% of PIK3CA-mutated
carcinomas, there was no significant difference in the prevalence of
BRAF mutation between both tumor groups (P=0.45). Decreased
or loss of MGMT immunohistochemical expression was found
more frequently in PIK3CA-mutated carcinomas compared with
PIK3CA wild-type carcinomas (35% vs. 20%, P=0.001). MGMT
methylation (38% vs. 28%) and MLH1 methylation (16% vs. 10%)
were also more frequent in PIK3CA-mutated carcinomas com-
pared with PIK3CA wild-type carcinomas, although neither
reached statistical significance (P=0.27 and P=0.06, respectively).
No significant association was found between the status of PIK3CA
mutation and MSI status or the group of patients suspected of
having Lynch syndrome based on their tumor molecular profile
(putative Lynch syndrome; Table 3).
Specific Associations with Subtypes of PIK3CA Mutation
Of all 105 tumors with PIK3CA mutations, 78 (74%) had a
mutation within the helical domain of exon 9, with 1 tumor
possessing 2 mutations, and 24 (23%) had a mutation in exon 20
catalytic domain. There were 3 tumors (3%) possessing mutations
in both exon 9 and exon 20. The most common mutations were
c.1624G.A (n= 37) and c.1633G.A (n= 24) in exon 9, and
c.3140A.G (n= 17) in exon 20 (Figure 3). The most frequent
PIK3CA mutation subtype was a G.A transversion in 63/105
(60%) of PIK3CA-mutated tumors. The G.A transversion was
more frequently observed in tumors with loss of MGMT
expression, compared with tumors showing normal MGMT
expression (77% vs 50%; P=0.048). No association was found
between MGMT methylation and the G.A transversion
mutation.
The significant associations between PIK3CA mutation and
both proximal colon location and mucinous differentiation were
Figure 1. Proportion of PIK3CA mutation in colorectal carcinomas from each segment of the large bowel.
doi:10.1371/journal.pone.0065479.g001
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found for each PIK3CA exonic mutation subgroup of tumors
(Table 2). When compared with wild-type PIK3CA tumors,
only exon 9 PIK3CA mutation was significantly associated with
KRAS mutation (53% vs. 25%), high levels of CIMP (21% vs
11%) and loss of MGMT expression (40% vs. 20%), whereas
these associations were not found or did not reach statistical
Table 2. PIK3CA mutation in 757 colorectal carcinomas (overall, exon 9 and exon 20 hot spots) and clinico-pathologic features.
Features Classes
PIK3CA wild-
type CRC
PIK3CA mutated
CRC P value* Exon 9 Mutation
Exon 20
Mutation
Total 652 105 81 27
Mean age, years 6 standard deviation 6869 6968 0.12 6968 7067
Male (%) 342 (53) 52 (50) 0.56 43/81 (53) 10/27 (37)
Anglo-Celtic Ethnicity (%) 443 (69) 78 (76) 0.22 58/78 (74) 23/27 (85)
Proximal colon location (%) 214 (34) 56 (54) ,0.001 45/81 (56) 14/25 (56)
High histologic grade (%) 147 (23) 21 (20) 0.51 19/80 (24) 2/26 (8)
Tumor margin (%) Circumscribed 421 (72) 73 (76) 0.38 54 (74) 22 (85)
Infiltrating 166 (28) 23 (24) 19 (26) 4 (15)
Mucinous differentiation (%) Absent 402 (68) 43 (46) ,0.001 32 (46) 11 (42)
Focal ,50% 140 (24) 41 (44) 32 (46) 12 (46)
Prominent .50% 46 (8) 9 (10) 6 (8) 3 (12)
Presence of TIL (%) 151 (24) 24 (24) 1.0 16/76 (21) 8/26 (31)
Presence of tumor budding (%) 203 (37) 33 (35) 0.75 28/74 (38) 5/23 (22)
Metastatic node (%) 251 (45) 37 (40) 0.38 31/72 (43) 7/24 (29)
Synchronous CRC (%) 13 (2) 3 (3) 0.59 3/79 (4) 0/25 (0)
Presence of contiguous polyp (%) 155 (25) 32 (32) 0.13 24/77 (31) 11/25 (44)
*P value comparing PIK3CA wild-type and PIK3CA-mutated tumors. There are 3 tumors with mutations in both exons 9 and 20. Results for exon 9 and exon 20 mutation
in italic bold indicate statistical significance (P,0.05) when compared with PIK3CA wild-type tumors. CRC: Colorectal carcinoma; TIL: Tumor infiltrating lymphocytes.
doi:10.1371/journal.pone.0065479.t002
Figure 2. Associations between PIK3CA mutation and KRAS mutation, high levels of CpG island methylator phenotype (CIMP), and
loss of MGMT expression.
doi:10.1371/journal.pone.0065479.g002
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significance for exon 20 PIK3CA mutation (37 vs. 25%, P=0.17,
23% vs. 17%, P=0.07 and 20% vs. 20% P=0.99, respectively)
(Table 3). On the other hand, only exon 20 PIK3CA-mutated
carcinomas were more frequently MSI-high than PIK3CA wild-
type carcinomas (30% vs. 12%; P=0.005). Of the 14 tumors
with both MSI-high and PIK3CA mutation, 8 possessed a
mutation in exon 20. Of these 8 cases, 4 demonstrated MLH1
methylation, and 4 were from patients with putative Lynch
syndrome.
Table 3. PIK3CAmutation (overall, exon 9 and exon 20 hot spots) and other molecular characteristics of 757 colorectal carcinomas.
Features PIK3CA wild-type CRC PIK3CA mutated CRC P value* Exon 9 Mutation Exon 20 Mutation
Total 652 105 81 27
KRAS mutation (%) 165 (25) 50 (48) ,0.001 43/81 (53) 10 (37)
BRAF mutation (%) 106 (17) 14 (14) 0.45 8/80 (10) 6/26 (23)
High levels of CIMP (%) 72 (11) 22 (22) 0.004 16/77 (21) 6/26 (23)
High levels of MSI (%) 75 (12) 14 (13) 0.58 6/80 (7) 8/27 (30)
MLH1methylation (%) 58 (10) 16 (16) 0.06 11/76 (14) 5/26 (19)
Putative Lynch syndrome# (%) 36 (6) 6 (6) 0.93 2/80 (3) 4/27 (15)
MGMT methylation (%) 43 (28) 10 (38) 0.27 7/21 (33) 3/6 (50)
MGMT loss of expression (%) 122 (20) 33 (35) 0.001 29/73 (40) 5/25 (20)
*P value comparing PIK3CA wild-type and PIK3CA-mutated tumors. There are 3 tumors with mutations in both exons 9 and 20. #Putative Lynch syndrome was defined
as tumors with one of the following characteristics: loss of expression of MSH2 and MSH6, MSH6 alone, PMS2 alone, or loss of MLH1 and PMS2 expression with wild-type
BRAF and/or absence of MHL1 methylation. Results for exon 9 and exon 20 mutation in italic bold indicate statistical significance (P,0.05) when compared with PIK3CA
wild-type tumors. CRC: Colorectal carcinoma; MSI: Microsatellite instability; CIMP: CpG island methylator phenotype.
doi:10.1371/journal.pone.0065479.t003
Figure 3. PIK3CA mutation subtypes.
doi:10.1371/journal.pone.0065479.g003
PIK3CA Mutation in Colorectal Carcinoma
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Survival Analyses
Of the 651 of the 757 patients (86%) with data available on
all relevant variables, 261 died during a median follow-up of
5.03 years (range 5.1 months –16.7 years). There was some
evidence of lower survival for those with PIK3CA-mutated
tumors compared with wild-type PIK3CA tumors (log rank
P=0.07) (Figure 4A). After adjustment for other factors in a
Cox regression model, this association was non-significant (HR
1.33, 95% CI 0.93–1.90, P=0.12). After restricting the analysis
to patients with a BRAF wild-type tumor, PIK3CA mutation was
significantly associated with poorer overall survival (HR 1.51,
95% CI 1.04–2.19, P=0.03) compared with wild-type PIK3CA
(Figure 4B). The effect of PIK3CA on mortality was not
significantly different according to BRAF status (Pinteraction = 0.1).
Although this interaction was not significant at the 5% level,
such interaction analyses have low statistical power.
Discussion
We detected PIK3CA mutation in 14% of colorectal carcinomas.
These tumors were characterized by a predominant proximal
colonic location, frequent presence of mucinous differentiation,
and associations with KRASmutation, high levels of CIMP and loss
of MGMT immunohistochemical expression. Except for MGMT,
the P values for these associations remained significant after the
correction for multiple hypotheses testing was applied (20 variables
compared between 2 groups; corrected P value = 0.05/
40= 0.00125). Though there was overlap with BRAF V600E
mutation, the prevalence of BRAF V600E mutation did not differ
between PIK3CA-mutated and PIK3CA wild-type tumors, suggest-
ing that the association between PIK3CA mutation and high levels
of CIMP is independent of BRAF.
Our estimate of the prevalence of PIK3CA mutation is in
agreement with results from previous studies
[4,8,9,10,11,12,13,14,15,16,17,18,19,20,21]. In this study, we
used Sanger sequencing to identify PIK3CA mutations in DNA
from FFPE tissue. When compared with pyrosequencing-based
detection on FFPE DNA in a comparable population, the
prevalence of PIK3CA mutation was slightly lower but not
significantly different (14% vs. 16%; P=0.14) [17,29]. In
agreement with Yamauchi et al, we found a gradual decrease in
frequencies of PIK3CA mutation in tumors from the cecum (25%)
to the rectum (9.5%), rather than an abrupt change from the
proximal colon to the distal colon [38]. The most striking and
consistent finding that we and others have found is the association
between PIK3CA mutation and KRAS mutation in colorectal
carcinoma, though some have not reported this finding [13,28]. In
our study, 47% of PIK3CA-mutated tumors also possessed KRAS
mutations. Interestingly, the co-existence of KRAS mutation and
PIK3CA mutation has also been found in other tumor types such as
ovarian carcinoma [14], suggesting that such co-occurrence might
provide a selective advantage to carcinoma cells from various
origins.
The association between tumor mucinous differentiation and
PIK3CA mutation has been previously reported [17,30]. Other
studies have shown that colorectal carcinomas with KRAS
mutation display mucinous differentiation more frequently than
carcinomas with wild-type KRAS [34,39]. Given the strong
association between PIK3CA mutation and KRAS mutation, this
association is not unexpected. Likewise, loss of MGMT expression,
another characteristic of PIK3CA-mutated carcinomas, has been
reported to be more frequent in tumors with mucinous differen-
tiation compared with tumors without mucinous differentiation
[29]. Consistent with previous findings, MGMT loss of expression
was associated with an increased frequency of G.A transversion
mutations in PIK3CA [17].
Differences between tumors possessing exon 9 or exon 20
PIK3CA mutations have been reported by others [21,29,31,40] but
these reports should be interpreted with caution as the number of
cases with mutations in exon 20 is low (25–30% of all PIK3CA
mutations), increasing the likelihood of chance findings. We found
that the associations between PIK3CA mutation and proximal
colonic tumor location and mucinous differentiation were present
in both exonic mutations, but the relationships with KRAS
mutation, high levels of CIMP and MGMT loss of expression
were confined to exon 9. It is possible that the absence of statistical
significance between exon 20 PIK3CA mutation and KRAS
mutation and CIMP might at least be partly caused by low
sample size. The discrepancy between exons 9 and 20 mutations
has not been universally reported with two previous large studies
showing association with KRAS mutation regardless of exonic
mutation in PIK3CA [21,41] whereas Janku et al reported a
significant association between KRASmutation and exon 9 PIK3CA
mutation [14]. A recent study of human p110-alpha in an avian
Figure 4. Kaplan-Meier survival curves showing overall survival according to PIK3CAmutation status (wild-type versus mutated) in
(A) all colorectal carcinoma patients and (B) only in patients with BRAF wild-type tumor.
doi:10.1371/journal.pone.0065479.g004
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model system has shown that activation induced by the helical
domain in exon 9 requires RAS-GTP, whereas that induced by
the kinase domain in exon 20 is functional in the absence of RAS-
GTP and interacts directly with p85 [42]. Our findings of a
stronger association between PIK3CA exon 9 mutation and
activating mutations in codons 12 or 13 of KRAS supports this
functional link between RAS signaling and activation of the helical
domain of p110-alpha. A singular association was also observed
between PIK3CA exon 20 mutation and MSI-high. This has been
reported previously from 2 large studies [21,29]. In this study, the
MSI-high tumors with PIK3CA exon 20 mutations were equally
distributed between those resulting from MLH1 methylation (non-
familial) and those likely to have resulted from a germline
mismatch repair gene mutation (putative Lynch syndrome)
suggesting no strong link between exon 20 mutations and either
familial or non-familial MSI-high colorectal carcinomas, although
the total number of tumors in this group was small (n = 8). Given
the lack of association with the BRAF V600E mutation, as well as
the fact that Lynch syndrome colorectal carcinomas arise from
conventional adenomas, the association between exon 20 muta-
tions and MSI-high might not be related to the serrated neoplasia
pathway as has been previously suggested [21]. Furthermore,
others have also described Lynch syndrome tumors having
predominantly exon 20 mutations [40].
We found an association between PIK3CA mutation and poor
overall survival for patients with a BRAF wild-type tumor. This
result suggests that PIK3CA may have a mild adverse effect on
survival after the strong effect of BRAF mutation is controlled [43].
Association between PIK3CA mutation and survival has been
reported in previous studies with differences in the type of
mutation or the group of patients: poor survival for all PIK3CA
mutations in all colorectal carcinomas by Iida et al and Kato et al
[13,28], for tumors with both exons 9 and 20 mutations only by
Liao et al [29], for tumors with exon 20 mutation only by Farina-
Sarasquesta et al [32], and in patients with KRAS wild-type tumors
only by Ogino et al [18]. Because of limited numbers we lacked
power to demonstrate any difference in survival for the subset of
patients with PIK3CA exon 20 mutation or patients with mutation
in both exons 9 and 20. Recently, Liao et al reported that among
patients with a PIK3CA-mutated colorectal cancer, regular use of
aspirin was associated with significantly longer colorectal cancer–
specific survival and overall survival, suggesting that aspirin use
after diagnosis may have a differential effect on survival depending
on PIK3CA mutation status [27]. It would be interesting to validate
these findings in other series. Reliable data on aspirin use in our
cohort of patients was not available to address this question.
In summary, we have found that PIK3CA mutation in colorectal
carcinomas correlated with tumor proximal colonic location,
mucinous differentiation, KRAS mutation, high levels CIMP and
loss of MGMT expression. The adverse prognostic effect of
PIK3CA mutation on survival was restricted to patients with a wild-
type BRAF mutated tumor.
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